In both adult and aged animals, bone volume was significantly decreased by rosiglitazone.

Responses to rosiglitazone were compared with placebo using paired t-tests.

There were no major adverse effects attributable to rosiglitazone.

DiBP and rosiglitazone additionally reduced fetal plasma insulin levels.

Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period.